DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Congenital glaucoma

Essential points for quick revision.

!
Corneal haze and light aversion need urgent attention

An infant with tearing, photophobia and an enlarged or cloudy cornea may have congenital glaucoma. Pressure can damage the optic nerve and disrupt visual development.

Action: Contact the acute ophthalmology service the same day for urgent assessment. Do not delay referral to obtain a community pressure measurement or trial treatment for blocked tear ducts.

Synopsis

Recognise pressure-related changes in the infant eye, arrange urgent specialist assessment and understand surgical treatment, paediatric medicine restrictions and lifelong visual follow-up.

  • Primary congenital glaucoma reflects abnormal development of aqueous drainage structures.
  • The compliant infant globe can enlarge when intraocular pressure remains high.
  • Epiphora, photophobia and blepharospasm are useful presenting clues.

Key red flags

Corneal clouding or enlargement, particularly with light sensitivity and persistent watering.

Investigation priorities

01
Specialist tonometryFirst step

Measure intraocular pressure using an appropriate paediatric technique.

Management branches

Suspected glaucomaArrange urgent paediatric ophthalmic assessment

An infant has corneal enlargement or haze with tearing, light aversion or lid spasm.

  1. Inspect both corneas and assess visual behaviour as far as the child comfortably allows.
  2. Contact the acute eye service and describe the observed signs rather than a presumed blocked duct.

Key medicines

Latanoprost 50 micrograms/mL eye drops — XalatanSpecialist paediatric use follows the licensed adult schedule: one drop in each affected eye once daily, preferably in the evening; do not increase beyond once daily.
Brimonidine-containing eye drops — safety exclusionDo not administer to neonates or infants younger than two years; no infant dose is appropriate because this age group is contraindicated.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 7 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom